AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10597779 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen
Number of subjects: 161
Study 10597779 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug groups
Number of subjects: 161
Study 10597779 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study 10597779 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug group
Number of subjects: 161
Study 7472724 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour rating scale
Number of subjects: 5
Study 7472724 — intervention group
Group type: COMPARATOR
Intervention: Other four scales
Number of subjects: 5
Study 1957876 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple choice question
Number of subjects: 1078
Study 1957876 — intervention group
Group type: COMPARATOR
Intervention: Dichotomous response format
Number of subjects: 1078
Study 1957876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral communication channel
Number of subjects: 1078
Study 1957876 — intervention group
Group type: EXPERIMENTAL
Intervention: Written communication channel
Number of subjects: 1078
Study 7036281 — intervention group
Group type: COMPARATOR
Intervention: LMF plus BCG (six cycles of Leukeran plus methotrexate plus fluorouracil plus repeated BCG skin scarifications)
Number of subjects: 242
Study 7036281 — intervention group
Group type: COMPARATOR
Intervention: LMF plus BCG
Number of subjects: 242
Study 7036281 — intervention group
Group type: EXPERIMENTAL
Intervention: LMF plus BCG (greater than 90% of planned LMF dose)
Number of subjects: 242
Study 7036281 — intervention group
Group type: COMPARATOR
Intervention: LMF alone (nonrandomized comparison)
Number of subjects: 242
Study 29150789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Stress (CS) - immersion in 15 °C water for 5 min
Number of subjects: 60
Study 29150789 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat Stress (HS) - immersion in 40 °C water for 5 min
Number of subjects: 60
Study 29410081 — intervention group
Group type: EXPERIMENTAL
Intervention: α-blockade preoperatively
Number of subjects: 135
Study 29410081 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 29410081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-stented patients
Number of subjects: 135
Study 26418143 — intervention group
Group type: EXPERIMENTAL
Intervention: 1470-nm laser ablation (10 W, continuous mode)
Number of subjects: 67
Study 26418143 — intervention group
Group type: COMPARATOR
Intervention: 1920-nm laser ablation (5 W)
Number of subjects: 67
Study 25047374 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox-intervention (multi-component, kindergarten-based, family-involved intervention)
Number of subjects: 7056
Study 25047374 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 7056
Study 22562783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of moxifloxacin 0.5%/dexamethasone 0.1% ophthalmic solution
Number of subjects: 102
Study 22562783 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 0.5% ophthalmic solution and dexamethasone 0.1% (concomitant group)
Number of subjects: 102
Study 20730641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Toddlers Program (MTP)
Number of subjects: 47
Study 20730641 — intervention group
Group type: COMPARATOR
Intervention: Parent Education Program (PE)
Number of subjects: 47
Study 18642781 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive ocular saccade in PD patients
Number of subjects: 24
Study 18642781 — intervention group
Group type: EXPERIMENTAL
Intervention: Random ocular saccade in PD patients
Number of subjects: 24
Study 18642781 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive saccades in PD patients
Number of subjects: 24
Study 16372388 — intervention group
Group type: EXPERIMENTAL
Intervention: P-splines based model for ERPs curves with random effects
Number of subjects: 0
Study 16372388 — intervention group
Group type: COMPARATOR
Intervention: Classical strategies for ERP analysis
Number of subjects: 0
Study 14641923 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg, t.d.s.)
Number of subjects: 32
Study 14641923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (t.d.s.)
Number of subjects: 32
Study 10965102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansentron 8 mg every 8 hours with dexamethasone 8 mg before cisplatin infusion and continued after 8 and 16 hours.
Number of subjects: 100
Study 10965102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansentron 8 mg every 6 hours with dexamethasone 8 mg before cisplatin infusion and continued after 6, 12, and 18 hours.
Number of subjects: 100
Study 10965102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received a total dose of 24 mg ondansentron during the acute phase of emesis.
Number of subjects: 100
Study 10965102 — intervention group
Group type: COMPARATOR
Intervention: Control for nausea and vomiting episodes.
Number of subjects: 100
Study 9102051 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma nail osteosynthesis
Number of subjects: 222
Study 9102051 — intervention group
Group type: COMPARATOR
Intervention: Former osteosynthesis techniques
Number of subjects: 222
Study 1795315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mineral baths and mud packs (Group 1)
Number of subjects: 53
Study 1795315 — intervention group
Group type: COMPARATOR
Intervention: Tap water baths only (Group 2)
Number of subjects: 53
Study 1795315 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral baths and mud packs (for osteoarthritis patients)
Number of subjects: 53
Study 6225751 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg bw
Number of subjects: 198
Study 6225751 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg bw
Number of subjects: 198
Study 6225751 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg bw
Number of subjects: 198
Study 6225751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebum suppression
Number of subjects: 198
Study 6225751 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective side effects
Number of subjects: 198
Study 6225751 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides and cholesterol
Number of subjects: 198
Study 6225751 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory parameters
Number of subjects: 198
Study 31177143 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided brachytherapy (IGBT)
Number of subjects: 253
Study 31177143 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-dimensional brachytherapy (2DBT)
Number of subjects: 253
Study 28399840 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic transanal proctectomy (ETAP)
Number of subjects: 226
Study 28399840 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic proctectomy (LAP)
Number of subjects: 226
Study 25464463 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (30 s at 100% of max workload, followed by 30 s at rest, 45 min 3 days/week for 12 weeks)
Number of subjects: 72
Study 25464463 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 25619045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular sodium hyaluronate (1%; 2,2-2,7 MDa), administered once weekly for 3 weeks (3 injections)
Number of subjects: 75
Study 25619045 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic slow-acting drugs for osteoarthritis (SYSADOA)
Number of subjects: 75
Study 22349603 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) at 6 weeks after surgery
Number of subjects: 71
Study 22349603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ESWT)
Number of subjects: 71
Study 19754679 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 39
Study 19754679 — intervention group
Group type: COMPARATOR
Intervention: Epsilon‐aminocaproic acid (Amicar)
Number of subjects: 39
Study 19754679 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin and Epsilon‐aminocaproic acid (Amicar)
Number of subjects: 39
Study 17668086 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching agents (3M Zaris, 3M Espe; Nite White Excel, Discus Dental)
Number of subjects: 10
Study 17668086 — intervention group
Group type: COMPARATOR
Intervention: Nontreated teeth
Number of subjects: 10
Study 15150563 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC group (Calvert's formula, AUC set at 4.5)
Number of subjects: 28
Study 15150563 — intervention group
Group type: COMPARATOR
Intervention: BS group (Body Surface area calculation)
Number of subjects: 28
Study 15150563 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC group (Calvert's formula)
Number of subjects: 28
Study 11493236 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil-morphine mixture (0.75 : 10 mg)
Number of subjects: 58
Study 11493236 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 58
Study 9808867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A levels > 3 mg/kg/day
Number of subjects: 0
Study 9808867 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-CoA-reductase inhibitors
Number of subjects: 0
Study 9808867 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study 9808867 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for blocking T-cell costimulation and expression of adhesion molecules, cytokines and antiendothelial antibodies, antiproliferative drugs, methods to augment endogenous nitric oxide bioavailability, newer immunosuppressive regimens
Number of subjects: 0
Study 9808867 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization procedures
Number of subjects: 0
Study 8048813 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexpensive measuring instruments
Number of subjects: 26
Study 8048813 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced observers
Number of subjects: 26
Study 8048813 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced observers
Number of subjects: 26
Study 8048813 — intervention group
Group type: COMPARATOR
Intervention: Expensive measuring instruments
Number of subjects: 26
Study 3181646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (4.0 g omega-3 fatty acids)
Number of subjects: 0
Study 3181646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (7.5 g omega-3 fatty acids)
Number of subjects: 0
Study 3181646 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (placebo)
Number of subjects: 0
Study 3181646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 0
Study 30264906 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 3 (15 min sitting interrupted by 3-min light-intensity walking breaks)
Number of subjects: 12
Study 30264906 — intervention group
Group type: COMPARATOR
Intervention: Condition 1 (7 h sitting interrupted every 60 min)
Number of subjects: 12
Study 30264906 — intervention group
Group type: COMPARATOR
Intervention: Condition 2 (7 h sitting interrupted every 30 min)
Number of subjects: 12
Study 27056846 — intervention group
Group type: EXPERIMENTAL
Intervention: MAXout treatment (18-week treatment, two 90-minute sessions per week)
Number of subjects: 0
Study 25828740 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (postcon)
Number of subjects: 75
Study 25828740 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI (control)
Number of subjects: 75
Study 23297321 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 120
Study 23297321 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic saline
Number of subjects: 120
Study 23297321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 120
Study 23297321 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol
Number of subjects: 120
Study 23297321 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine, sodium bicarbonate, or physiologic saline
Number of subjects: 120
Study 23297321 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL
Number of subjects: 120
Study 21884868 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestion (VS)
Number of subjects: 30
Study 21884868 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 19407804 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR-based antihypertensive treatment
Number of subjects: 1025
Study 19407804 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based antihypertensive treatment
Number of subjects: 1025
Study 19407804 — intervention group
Group type: COMPARATOR
Intervention: Control group (genotype T/T, T/C, C/C)
Number of subjects: 1025
Study 19407804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (Verapamil and Atenolol)
Number of subjects: 1025
Study 16731300 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard efficiency acetate-free biofiltration (AFB) for 4 hours
Number of subjects: 0
Study 16731300 — intervention group
Group type: COMPARATOR
Intervention: Higher efficiency acetate-free biofiltration (AFB) for 4 hours
Number of subjects: 0
Study 16731300 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour acetate-free biofiltration (AFB) session
Number of subjects: 0
Study 16731300 — intervention group
Group type: COMPARATOR
Intervention: 5-hour acetate-free biofiltration (AFB) session
Number of subjects: 0
Study 15126313 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment to eradicate H pylori infection
Number of subjects: 10537
Study 15126313 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori infection
Number of subjects: 10537
Study 11273059 — intervention group
Group type: EXPERIMENTAL
Intervention: Banked breastmilk
Number of subjects: 216
Study 11273059 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 216
Study 11273059 — intervention group
Group type: COMPARATOR
Intervention: Standard term formula
Number of subjects: 216
Study 9781431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 200 mg administered 1 hour before urethrocystoscopy
Number of subjects: 78
Study 9781431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg administered 1 hour before urethrocystography
Number of subjects: 78
Study 9781431 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (control group) for both procedures
Number of subjects: 78
Study 7823492 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide investigation
Number of subjects: 122
Study 3244560 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (4 mg.kg b.w.‐1)
Number of subjects: 9
Study 3244560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29355361 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced consultation/coaching
Number of subjects: 0
Study 29355361 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation
Number of subjects: 0
Study 28956934 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 139
Study 28956934 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirit-only MI (SOMI)
Number of subjects: 139
Study 28956934 — intervention group
Group type: COMPARATOR
Intervention: Nontherapy control condition
Number of subjects: 139
Study 26096115 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser excision
Number of subjects: 20
Study 26096115 — intervention group
Group type: COMPARATOR
Intervention: Scalpel excision
Number of subjects: 20
Study 22930491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR) plus treatment as usual (TAU)
Number of subjects: 47
Study 22930491 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 47
Study 22930491 — intervention group
Group type: EXPERIMENTAL
Intervention: Completer analyses (≥ 4 classes attended)
Number of subjects: 47
Study 22027737 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus‐eluting stent
Number of subjects: 80
Study 22027737 — intervention group
Group type: COMPARATOR
Intervention: Coroflex Blue postdilated with the paclitaxel-eluting balloon Sequent Please
Number of subjects: 80
Study 18454988 — intervention group
Group type: EXPERIMENTAL
Intervention: Early steroid reduction (G1; n = 31)
Number of subjects: 60
Study 18454988 — intervention group
Group type: COMPARATOR
Intervention: Regular steroid dosage maintenance (G2; n = 29)
Number of subjects: 60
Study 17159691 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanteric fixation nail (TFN)
Number of subjects: 60
Study 17159691 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 60
Study 14728104 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5-20 mg/day)
Number of subjects: 10
Study 14728104 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers, n=10)
Number of subjects: 10
Study 12564573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (specifics not provided)
Number of subjects: 1507
Study 12564573 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1507
Study 9701538 — intervention group
Group type: EXPERIMENTAL
Intervention: Full version of warning signs (with all components included)
Number of subjects: 84
Study 9701538 — intervention group
Group type: COMPARATOR
Intervention: Original version of warning signs (with components omitted)
Number of subjects: 84
Study 9701538 — intervention group
Group type: COMPARATOR
Intervention: Versions omitting hazard, consequences, and instructions statements
Number of subjects: 84
Study 7536515 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 34
Study 2914436 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiquick patch test on the left side
Number of subjects: 100
Study 2914436 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiquick patch test on the right side
Number of subjects: 100
Study 2914436 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant reactions on both sides
Number of subjects: 100
Study 2914436 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative reactions on the left side
Number of subjects: 100
Study 2914436 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenge after 6 weeks
Number of subjects: 100
Study 2914436 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reproducibility of positive reactions
Number of subjects: 100
Study 770080 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg azapropazone daily
Number of subjects: 108
Study 770080 — intervention group
Group type: COMPARATOR
Intervention: 3.9 g aspirin daily
Number of subjects: 108
Study 31375713 — intervention group
Group type: EXPERIMENTAL
Intervention: AR pseudocolor low vision aid
Number of subjects: 10
Study 28326559 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7652 (10, 40, 150, 300, 600, or 800 mg single dose)
Number of subjects: 80
Study 28326559 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7652 (40 or 150 mg multiple doses once weekly for 4 weeks)
Number of subjects: 80
Study 28326559 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7652 with atorvastatin
Number of subjects: 80
Study 28326559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26490026 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemo-endocrine therapy (goserelin for premenopausal women or an aromatase inhibitor for postmenopausal women)
Number of subjects: 28
Study 26490026 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 28
Study 26490026 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent therapy
Number of subjects: 28
Study 26490026 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 28
Study 23266743 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 tablets of dietary supplement (DS) containing red yeast rice extract, policosanol and artichoke leaf extract
Number of subjects: 45
Study 23266743 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 tablets of dietary supplement (DS) containing red yeast rice extract, policosanol and artichoke leaf extract
Number of subjects: 45
Study 23266743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 45
Study 23266743 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 tablets of dietary supplement (DS)
Number of subjects: 45
Study 23266743 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 tablets of dietary supplement (DS)
Number of subjects: 45
Study 23266743 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 tablets of dietary supplement (DS) and 3 tablets of dietary supplement (DS)
Number of subjects: 45
Study 21469913 — intervention group
Group type: EXPERIMENTAL
Intervention: Earthing (contact with the Earth via a copper conductor)
Number of subjects: 168
Study 21469913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contact with the Earth)
Number of subjects: 168
Study 17428714 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 or 80 mg)
Number of subjects: 9
Study 17428714 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 9
Study 17428714 — intervention group
Group type: COMPARATOR
Intervention: Standard incremental cycling exercise
Number of subjects: 9
Study 17150167 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflectance-mode confocal microscopy (RCM)
Number of subjects: 0
Study 17150167 — intervention group
Group type: COMPARATOR
Intervention: Ivory soap at selected concentrations
Number of subjects: 0
Study 12832710 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated leucocytes co-cultured with fibroblast-like synoviocytes (FLS) from RA patients.
Number of subjects: 0
Study 10683600 — intervention group
Group type: EXPERIMENTAL
Intervention: SPORT (dietary supplement)
Number of subjects: 9
Study 10683600 — intervention group
Group type: COMPARATOR
Intervention: Gelatin placebo
Number of subjects: 9
Study 9587555 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha 2b 10 MIU TIW for 2 months, then 6 MIU TIW for 4 months (Group 1)
Number of subjects: 23
Study 9587555 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha 2b 6 MIU TIW for 6 months (Group 2)
Number of subjects: 23
Study 9587555 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23